As a Free StocksGuide user, you can view scores for all 7,002 stocks worldwide.
13 Analysts have issued a CureVac N.V. forecast:
13 Analysts have issued a CureVac N.V. forecast:
Jun '25 |
+/-
%
|
||
Revenue | 591 591 |
675%
675%
|
|
Gross Profit | 560 560 |
613%
613%
|
|
EBITDA | 264 264 |
185%
185%
|
|
EBIT (Operating Income) EBIT | 241 241 |
172%
172%
|
|
Net Profit | 224 224 |
170%
170%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
Head office | Netherlands |
CEO | Alexander Zehnder |
Employees | 904 |
Founded | 2020 |
Website | www.curevac.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.